Description

Stryker Corporation’s Hidden Growth Engine — Mako Utilization Keeps Reaching New Highs!

Stryker Corporation reported second quarter 2026 results that reflected a broad-based recovery and resilient demand across its diversified medical technology portfolio despite earlier operational challenges. The company posted 9% organic sales growth, driven by strong performances in both its MedSurg and Neurotechnology and Orthopaedics segments. Geographically, U.S. organic growth was 9%, with double-digit growth in Medical, Trauma & Extremities, and Endoscopy businesses, partially offset by supply disruptions in the Peripheral Vascular segment that caused significant backorders and lost sales during the quarter. Internationally, organic sales increased 8.9%, supported by strong demand in various key markets including Australia, Germany, South Korea, and Brazil. Adjusted earnings per share increased 17.9% to $3.69, benefiting from improved gross margins, tariff refunds, and operational efficiencies, although the full-year EPS guidance range was narrowed to $14.95–$15.10 due to ongoing remediation costs related to a cybersecurity incident and other macroeconomic factors like raw material cost pressures.